Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML
Cells · 2026
DOI: 10.3390/cells15151414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Malgorzata Statkiewicz und 23 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cyclin-Dependent Kinase 8, Cell Differentiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Warsaw University of Technology, Maria Sklodowska-Curie National Research Institute of Oncology.
Abstract (Originalsprache)
Acute myeloid leukaemia (AML) is a therapeutically challenging malignancy driven by the self-renewal, quiescence, and therapy resistance of leukaemic stem cells (LSCs). CDK8, a kinase component of the Mediator complex, regulates oncogenic transcription, and the selective CDK8/CDK19 inhibitor RVU120 (Romaciclib) targets AML cells with CD34+/pSTAT5-high LSC-like characteristics; however, the epigenetic and transcriptional consequences of CDK8 blockade and actionable combinatorial strategies remain incompletely defined. Using the TEX cell line, an LSC-enriched surrogate model, we performed time-resolved RNA-seq, whole-proteome and phosphoproteomics mass spectrometry (MS), and CUT&Tag chromatin profiling following treatment with RVU120 and CCT251921. CDK8 protein–protein interactions were mapped by co-immunoprecipitation MS across five AML models, and synergy with Pelabresib (BET inhibitor) or CB6644 (RUVBL1/2 inhibitor) was assessed by high-content screening in three cell lines and three patient-derived xenograft (PDX) models. Both inhibitors suppressed STAT5 phosphorylation, induced loss of the CD34+/CD38− LSC-enriched phenotype, and drove erythromegakaryocytic differentiation. Transcriptomic and proteomic responses were concordant, and CDK8 inhibition triggered widespread enhancer activation with redistribution of RNAP2, BRD3, and NFRKB. CDK8 combined with Pelabresib acted synergistically in MOLM-16 cells and two of three PDX models. These findings identify CDK8 as a transcriptional node of LSC-associated programs and provide a mechanistic rationale for combined CDK8-BET inhibition in molecularly defined AML subsets, which will require validation in functional LSC assays and primary specimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Ryvu Therapeutics, 30-394 Krakow, Poland.
- Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781 Warsaw, Poland.
- Laboratory of Preclinical Research, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Department of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Genomics Core Facility, Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland.
ORCID-Profile: Malgorzata Statkiewicz, Izabela Rumienczyk, Marta Obacz, Jarosław Cendrowski, Ewelina Kaniuga, Wioletta Slusarczyk-Kacprzyk, Krzysztof Goryca, Tymon Rubel, Magdalena Bakun, Bianka Swiderska, Kamila Kruczkowska-Tarantowicz, Anna Polak, Przemyslaw Juszczynski, Jerzy Ostrowski, Michal Mikula
Förderung
- National Science Centre
- Warsaw University of Technology
- Maria Sklodowska-Curie National Research Institute of Oncology
Zitieren
APA
Statkiewicz, M., Rumienczyk, I., Pakulska, U., Obacz, M., Kulecka, M., Cendrowski, J., Cubulska-Lubak, M., Kaniuga, E., Sandowska-Markiewicz, Z., Slusarczyk-Kacprzyk, W., Goryca, K., Rubel, T., Bakun, M., Swiderska, B., Kruczkowska-Tarantowicz, K., Rzepecki, P., Korsak, J., Kyc-Wachowiak, K., Polak, A., …, & Mikula, M. (2026). Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML. Cells. https://doi.org/10.3390/cells15151414
Vancouver
Statkiewicz M, Rumienczyk I, Pakulska U, Obacz M, Kulecka M, Cendrowski J, et al. Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML. Cells. 2026. doi:10.3390/cells15151414
BibTeX
@article{Statkiewicz2026,
author = {Statkiewicz, Malgorzata and Rumienczyk, Izabela and Pakulska, Urszula and Obacz, Marta and Kulecka, Maria and Cendrowski, Jarosław and Cubulska-Lubak, Magdalena and Kaniuga, Ewelina and Sandowska-Markiewicz, Zuzanna and Slusarczyk-Kacprzyk, Wioletta and Goryca, Krzysztof and Rubel, Tymon and Bakun, Magdalena and Swiderska, Bianka and Kruczkowska-Tarantowicz, Kamila and Rzepecki, Piotr and Korsak, Jolanta and Kyc-Wachowiak, Krystyna and Polak, Anna and Juszczynski, Przemyslaw and Mazan, Milena and Rzymski, Tomasz and Ostrowski, Jerzy and Mikula, Michal},
title = {Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15151414}
}
EUVIMED